Summary
MSQ, the 16-item Migraine—Specific Quality—of—Life Questionnaire (Version 1.0), was developed by Glaxo Wellcome Inc. to assess the effect of migraine and its treatment on patients’ health—related quality of life (HR-QOL). The MSQ was hypothesised to measure 3 meaningful dimensions: (i) Role Function—Restrictive; (ii) Role Function—Preventive; and (iii) Emotional Function. The objective of this research was to further investigate the number of dimensions as well as the items contained in each dimension through principal components factor analysis of clinical trial data. Secondary objectives were to determine whether the factor structure changed in post—treatment visits compared with screening visits, to make recommendations for coding the MSQ when the patient did not have a migraine in the previous 4 weeks, and to modify the MSQ if so indicated by this research. Results supported the existence of 3 distinct factors which agreed strongly with the hypothesised dimensions. The analysis of post—treatment data suggested that the underlying factor structure of the MSQ varies as a result of treatment. Based on evaluations of the ‘did not have a migraine’ response, it was concluded that it be dropped from the MSQ. All these changes have been incorporated into MSQ (Version 2.0) which is being evaluated in studies to determine if its psychometric properties are different than the properties of the previous version.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States: relation to age, income, and other sociodemographic factors. JAMA 1992; 267: 64–9
Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993; 33: 29—35
Solomon GD, Skobieranda FG, Gragg LA. Quality of life and well-being of headache patients: measurement by the medical outcomes study instrument. Headache 1993; 33: 351–8
Osterhaus JT, Townsend RJ, Gandek B, et al. Measuring the functional status and well-being of patients with migraine headache in the U.S. Headache 1994; 34: 337–43
Soloman GD, Skobieranda FG, Gragg LA. Does quality of life differ among headache diagnoses: analysis using the Medial Outcomes Study Instrument. Headache 1994; 34: 143–7
Jhingran P, Osterhaus JT, Miller DW, et al. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache 1998; 38: 295–302
LaVange LM, Helms RW. Factor analyses of Glaxo Wellcome Pharmacoeconomic Research Migraine Specific Questionnaire Data: project final report. Chapel Hill (NC): Rho Inc., 1995
Adelman JE, Sharfman M, Johnson R, et al. Impact of oral sumatriptan on workplace productivity, health related quality of life, health care use, and patient satisfaction with medication in nurses with migraine. Am J Manage Care 1996; 2: 1407–14
Morrison DF. Multivariate statistical methods. New York: McGraw-Hill, 1979
Basilevsky A. Statistical factor analysis and related methods, theory and applications. New York: John Wiley and Sons Inc., 1994
SAS Institute Inc. SAS stat user’s guide. Version 6. 4th ed., vol. 1. Cary (NC): SAS Institute Inc., 1989
SAS Institute Inc. SAS stat user’s guide. Version 6. 4th ed., vol. 2. Cary (NC): SAS Institute Inc., 1989
Helms RW, MacDougall JE. Graphical presentation of covariance matrices from principal components and factor analysis models. Chapel Hill (NC): Department of Biostatistics, University of North Carolina, 1997. Institute of Statistics Mimeo Series no.: 2175
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jhingran, P., Davis, S.M., LaVange, L.M. et al. MSQ: Migraine-Specific Quality-of-Life Questionnaire. Pharmacoeconomics 13, 707–717 (1998). https://doi.org/10.2165/00019053-199813060-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199813060-00007